Gilead Sciences, Inc. $GILD Shares Purchased by AGF Management Ltd.

AGF Management Ltd. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 81.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,903 shares of the biopharmaceutical company’s stock after purchasing an additional 10,303 shares during the period. AGF Management Ltd.’s holdings in Gilead Sciences were worth $2,542,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. GoalVest Advisory LLC increased its position in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the period. Corundum Trust Company INC acquired a new position in Gilead Sciences during the third quarter worth $26,000. Harbor Asset Planning Inc. purchased a new stake in shares of Gilead Sciences in the second quarter valued at about $27,000. Putney Financial Group LLC boosted its stake in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute purchased a new stake in Gilead Sciences in the 2nd quarter worth approximately $30,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares in the company, valued at $18,709,027.93. This trade represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the sale, the insider directly owned 103,221 shares in the company, valued at approximately $12,831,402.51. The trade was a 2.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 257,397 shares of company stock worth $33,385,512. Company insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of a number of research analyst reports. BMO Capital Markets lifted their target price on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a report on Monday, January 26th. Citigroup boosted their target price on shares of Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. HSBC increased their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. TD Cowen lifted their price objective on shares of Gilead Sciences from $125.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Finally, Truist Financial upped their target price on shares of Gilead Sciences from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $136.73.

Gilead Sciences Stock Performance

GILD stock opened at $146.23 on Thursday. The company has a 50-day simple moving average of $126.41 and a 200 day simple moving average of $120.40. The company has a market capitalization of $181.42 billion, a P/E ratio of 22.67, a PEG ratio of 0.76 and a beta of 0.36. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $146.73.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.